ライフサイエンスコーパス: reverse transcriptase inhibitor

1 tase inhibitors (NRTIs) and a non-nucleoside reverse transcriptase inhibitor.

2 ncoming viral RNAs even in the presence of a reverse transcriptase inhibitor.

3 ders viral resistance to multiple nucleoside reverse transcriptase inhibitors.

4 late the prophylactic efficacy of nucleotide reverse transcriptase inhibitors.

5 ing of at least two nucleoside or nucleotide reverse transcriptase inhibitors.

6 l antiretroviral therapy with two nucleoside reverse transcriptase inhibitors.

7 lity of combining Spm8CHAS with HIV-specific reverse transcriptase inhibitors.

8 ir when each is combined with two nucleoside reverse transcriptase inhibitors.

9 herapy containing NVP or other nonnucleoside reverse transcriptase inhibitors.

10 rs (PI) with the same backbone of Nucleoside Reverse Transcriptase Inhibitors.

11 viously described for the IAS non-nucleoside reverse transcriptase inhibitors.

12 ved 400 mg RAL twice daily plus 2 nucleoside reverse transcriptase inhibitors.

13 he DNA-DSB site, and TSIs were suppressed by reverse-transcriptase inhibitors.

14 e-transcriptase inhibitors and nonnucleoside reverse-transcriptase inhibitors.

15 of two pyrimidine-based HIV-1 non-nucleoside reverse transcriptase inhibitors, 1 (MC1501) and 2 (MC20

16 inhibitor-based regimens (vs non-nucleoside reverse transcriptase inhibitor; 1.17, 1.00-1.36).

17 Quantification of 6 nucleoside/nucleotide reverse transcriptase inhibitors, 2 non-nucleoside rever

18 eekly CD4 counts and to receive 2 nucleoside reverse transcriptase inhibitors (2NRTI, mainly abacavir

19 retrotransposition can be suppressed by the reverse transcriptase inhibitor 3'-azido-3'-deoxythymidi

20 on for NNRTIs (5.4%), followed by nucleoside reverse transcriptase inhibitors (3.0%) and protease inh

21 Treatment with the reverse transcriptase inhibitor 3TC resulted in decrease

22 e transcriptase inhibitors, 2 non-nucleoside reverse transcriptase inhibitors, 7 protease inhibitors,

23 o major mutations (3% vs 51%), nonnucleoside reverse transcriptase inhibitor (94% vs 44%), M184V/I (9

24 ed by cognate nucleotides and non-nucleoside reverse transcriptase inhibitors, a major class of anti-

25 by failure of three subclasses of nucleoside reverse transcriptase inhibitors, a non-nucleoside rever

26 larly in the quantification of nonnucleoside reverse transcriptase inhibitor and lamivudine mutations

27 newer PIs, second-generation non-nucleoside reverse transcriptase inhibitors and drugs in novel clas

28 Nucleoside reverse transcriptase inhibitors and integrase inhibitor

29 in the cART regimen, in favor of nucleoside reverse transcriptase inhibitors and integrase inhibitor

30 Nonnucleoside reverse transcriptase inhibitors and integrase inhibitor

31 Drug treatment combinations with reverse transcriptase inhibitors and protease inhibitors

32 ations increased resistance to nonnucleoside reverse transcriptase inhibitors and vice versa.

33 This survey classified nonnucleoside reverse-transcriptase inhibitor and nucleoside reverse-t

34 combinations of 2 nucleoside (or nucleotide) reverse-transcriptase inhibitors and a ritonavir-boosted

35 re isolated and activated in the presence of reverse-transcriptase inhibitors and integrase inhibitor

36 ied as moderate (5%-15%) for both nucleoside reverse-transcriptase inhibitors and nonnucleoside rever

37 e transcriptase inhibitors, a non-nucleoside reverse transcriptase inhibitor, and a ritonavir-boosted

38 ther multitarget therapy with enfuvirtide, 2 reverse-transcriptase inhibitors, and a ritonavir-booste

39 resistance, background regimen of nucleoside reverse-transcriptase inhibitors, and the standard ramp-

40 reverse transcriptase inhibitor-, nucleoside reverse transcriptase inhibitor-, and protease inhibitor

41 ETV differs from the other nucleoside/tide reverse transcriptase inhibitors approved for HBV therap

42 our detection specificity with the use of a reverse transcriptase inhibitor as a counterscreen, enab

43 sociated with the use of nucleoside analogue reverse transcriptase inhibitors as a component of highl

44 core </=2 in 10 patients included nucleoside reverse transcriptase inhibitors associated with darunav

45 imilar proportions of overall and nucleoside reverse transcriptase inhibitor-associated minority vari

46 ipant in the atazanavir group had nucleoside reverse transcriptase inhibitor-associated resistance th

47 To determine whether nucleoside reverse-transcriptase inhibitor-associated peripheral ne

48 e implicated in susceptibility to nucleoside reverse-transcriptase inhibitor-associated toxicity.

49 constructs in the presence or absence of the reverse-transcriptase inhibitor azidothymidine.

50 of virologic failure with either nucleoside reverse transcriptase inhibitor backbone than women assi

51 a boosted darunavir regimen with nucleoside reverse transcriptase inhibitor background treatment for

52 A new series of non-nucleoside reverse transcriptase inhibitors based on an imidazole-a

53 Nonnucleoside reverse transcriptase inhibitor-based antiretroviral the

54 lopinavir/ritonavir (LPV/r) or nonnucleoside reverse transcriptase inhibitor-based ART and treated wi

55 1.01-1.07), being prescribed non-nucleoside reverse transcriptase inhibitor-based regimens (1.63, 1.

56 nce interval [CI], 90%-99.7%); nonnucleoside reverse transcriptase inhibitor-based, 100% (95% CI, 91%

57 use of a tenofovir-containing nonnucleoside reverse-transcriptase inhibitor-based first-line regimen

58 -62]; P = .001), compared with nonnucleoside reverse-transcriptase inhibitor-based regimens.

59 Antihepadnaviral treatment using an approved reverse transcriptase inhibitor blocked replication of a

60 localization of LysRS, but treatment with a reverse transcriptase inhibitor does not, suggesting tha

61 AS, or treatment of MAVS-deficient mice with reverse transcriptase inhibitors, dramatically inhibits

62 %) levels of resistance to the nonnucleoside reverse transcriptase inhibitor drug class.

63 No individual ARV in the reverse transcriptase inhibitor drug classes was associa

64 n patients exposed to various non-nucleoside reverse transcriptase inhibitor drugs (NNRTIs).

65 tance to older thymidine analogue nucleoside reverse transcriptase inhibitor drugs has been identifie

66 eiving tenofovir prodrugs, the nonnucleoside reverse transcriptase inhibitors efavirenz and rilpiviri

67 vitegravir, or raltegravir), a nonnucleoside reverse transcriptase inhibitor (efavirenz or rilpivirin

68 or abacavir/lamivudine) plus a nonnucleoside reverse transcriptase inhibitor (efavirenz), a ritonavir

69 We further show that the addition of reverse transcriptase inhibitors effectively suppresses

70 ART regimens based on either Non-Nucleoside Reverse Transcriptase Inhibitors (EFV) or ritonavir-boos

71 Receipt of nucleoside reverse-transcriptase inhibitors, especially stavudine a

72 Resistance to the nonnucleoside reverse transcriptase inhibitors etravirine and rilpivir

73 Transplacental nucleoside reverse-transcriptase inhibitor exposures induced fetal

74 -retroviral therapy with multiple nucleoside reverse transcriptase inhibitors for the treatment of pa

75 n inhibitor (PIE12-Trimer), a combination of reverse transcriptase inhibitors (FTC-TDF), a thioester

76 n that combined nucleoside and nonnucleoside reverse-transcriptase inhibitors (hereafter, "NNRTI stra

77 bserved with other non-allergenic nucleoside reverse transcriptase inhibitors, identifying abacavir a

78 anscriptase inhibitors in 62%, nonnucleoside reverse transcriptase inhibitors in 57%, protease inhibi

79 9 youth, identified resistance to nucleoside reverse transcriptase inhibitors in 62%, nonnucleoside r

80 sted proteasome inhibitors and nonnucleotide reverse transcriptase inhibitors in the cART regimen, in

81 pregnancy, 1 of which was without nucleoside reverse transcriptase inhibitors, infants had a specific

82 initiated at multiple sites and that several reverse transcriptase inhibitors influence the kinetics

83 these new features with a simple case (HIV-1 reverse transcriptase/inhibitor interaction) and with th

84 ontaining dapivirine, a non-nucleoside HIV-1 reverse-transcriptase inhibitor, involving women between

85 h combined with 2 nucleoside (or nucleotide) reverse transcriptase inhibitors is recommended with cho

86 as 2-LTR quantification and the addition of reverse transcriptase inhibitors, is crucial to fully el

87 Nonnucleoside reverse transcriptase inhibitor (K103N, V106M, Y181C, an

88 e (RPV) and EFV plus 2 nucleoside/nucleotide reverse transcriptase inhibitors (N[t]RTIs) in treatment

89 h common background nucleoside or nucleotide reverse transcriptase inhibitors (N[t]RTIs).

90 In addition, treatment with the reverse transcriptase inhibitor nevirapine delayed uncoa

91 The nonnucleoside reverse transcriptase inhibitor nevirapine is the corner

92 lopinavir and saquinavir, the nonnucleoside reverse-transcriptase inhibitor nevirapine, and the anti

93 avirenz is a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) and a common com

94 The non-nucleoside reverse transcriptase inhibitor (NNRTI) based FDC of ril

95 "switch region" and the viral non-nucleoside reverse transcriptase inhibitor (NNRTI) binding site.

96 led RT in the presence of the non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz (EFV)

97 es under the treatment with a non-nucleoside reverse transcriptase inhibitor (NNRTI) in cell culture.

98 ated that a formulation of the nonnucleoside reverse transcriptase inhibitor (NNRTI) MIV-150 in carra

99 mutations (4.5%), followed by nonnucleoside reverse transcriptase inhibitor (NNRTI) mutations (2.9%)

100 Efavirenz (EFV) is a nonnucleoside reverse transcriptase inhibitor (NNRTI) of HIV-1 reverse

101 y abacavir+lamivudine) with a non-nucleoside reverse transcriptase inhibitor (NNRTI) or 3 NRTIs as lo

102 psychiatric side-effects on a non-nucleoside reverse transcriptase inhibitor (NNRTI) or who are on a

103 eficiency virus type 1 (HIV-1) nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance mutat

104 ttributable to an increase in non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance.

105 e risk factors associated with nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance.

106 e inhibitor [NRTI]; n=470), a non-nucleoside reverse transcriptase inhibitor (NNRTI) strategy (NNRTI

107 8 is a diarylpyrimidine (DAPY) nonnucleoside reverse transcriptase inhibitor (NNRTI) that is highly e

108 ansmission of HIV-1, transient nonnucleoside reverse transcriptase inhibitor (NNRTI) therapy given du

109 The non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC278/rilpiviri

110 The nonnucleoside reverse transcriptase inhibitor (NNRTI) UC781 is under d

111 th a protease inhibitor (PI), non-nucleoside reverse transcriptase inhibitor (NNRTI), or both are lac

112 The non-nucleoside reverse transcriptase inhibitor (NNRTI), rilpivirine (TM

113 mg every 48 hours as part of a nonnucleoside reverse transcriptase inhibitor (NNRTI)- or lopinavir/ri

114 Non-nucleoside reverse transcriptase inhibitor (NNRTI)-based highly act

115 n protease inhibitor (PI)- and nonnucleoside reverse transcriptase inhibitor (NNRTI)-based regimens w

116 rologic failure for first-line nonnucleoside reverse transcriptase inhibitor (NNRTI)-based regimens.

117 Whether the same is true for nonnucleoside reverse transcriptase inhibitor (NNRTI)-based therapy is

118 nfants analyzed; 4 (80.0%) had nonnucleoside reverse transcriptase inhibitor (NNRTI)-resistant HIV-1,

119 Non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistant mutant

120 henone template as a potential nonnucleoside reverse transcriptase inhibitor (NNRTI).

121 e inhibitor and superior to a non-nucleoside reverse transcriptase inhibitor (NNRTI).

122 ) or on a regimen containing a nonnucleoside reverse transcriptase inhibitor (NNRTI; N = 52) or prote

123 dine or emtricitabine) plus a non-nucleoside reverse transcriptase inhibitor (NNRTI; nevirapine or ef

124 of alkenyldiarylmethane (ADAM) nonnucleoside reverse transcriptase inhibitors (NNRTI) 3 and 4 with HI

125 tice regarding the use of the non-nucleoside reverse transcriptase inhibitors (NNRTI) efavirenz (EFV)

126 al increases in resistance to non-nucleoside reverse transcriptase inhibitors (NNRTI) in east Africa

127 New non-nucleoside reverse transcriptase inhibitors (NNRTI), which are simi

128 aluated the impact of several non-nucleoside reverse transcriptase inhibitors (NNRTI; Efavirenz, Etra

129 AM1]) profiles at t0, use of a nonnucleoside reverse-transcriptase inhibitor (NNRTI) at t0 (vs combin

130 table markedly faster than did nonnucleoside reverse-transcriptase inhibitor (NNRTI) mutations (hazar

131 Eight (15%) had nonnucleoside reverse-transcriptase inhibitor (NNRTI) mutations, with

132 ed patients failing an initial nonnucleoside reverse-transcriptase inhibitor (NNRTI) regimen in Afric

133 over increasing prevalence of non-nucleoside reverse-transcriptase inhibitor (NNRTI) resistance in pe

134 or (NRTI) resistance, 9.8% had nonnucleoside reverse-transcriptase inhibitor (NNRTI) resistance, and

135 termine the effect of baseline nonnucleoside reverse-transcriptase inhibitor (NNRTI) resistance, as a

136 llows: exposure to nonstandard nonnucleoside reverse-transcriptase inhibitor (NNRTI)-based (hazard ra

137 RT) than among those receiving nonnucleoside reverse-transcriptase inhibitor (NNRTI)-based ART.

138 ing of ART as a change from a non-nucleoside reverse-transcriptase inhibitor (NNRTI)-based regimen to

139 patients initiating first-line nonnucleoside reverse-transcriptase inhibitor (NNRTI)-based therapy su

140 nction than patients receiving nonnucleoside reverse-transcriptase inhibitor (NNRTI)-based therapy.

141 We sought to detect minor nonnucleoside reverse-transcriptase inhibitor (NNRTI)-resistant varian

142 ffect of pre-existing minority nonnucleoside reverse-transcriptase inhibitor (NNRTI)-resistant varian

143 riptase inhibitors (NRTIs), 4 non-nucleoside reverse transcriptase inhibitors (NNRTIs) and 2 protease

144 Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are highly spe

145 Nonnucleoside reverse transcriptase inhibitors (NNRTIs) are potent and

146 Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are recommende

147 Although nonnucleoside reverse transcriptase inhibitors (NNRTIs) are usually pa

148 Worldwide, the nonnucleoside reverse transcriptase inhibitors (NNRTIs) efavirenz and

149 riptase inhibitors (NRTIs) and nonnucleoside reverse transcriptase inhibitors (NNRTIs) has been assoc

150 he prevalence of resistance to nonnucleoside reverse transcriptase inhibitors (NNRTIs) have been obse

151 Non-nucleoside reverse transcriptase inhibitors (NNRTIs) have been show

152 Diarylpyrimidine (DAPY) non-nucleoside reverse transcriptase inhibitors (NNRTIs) have inherent

153 Recent studies showed that nonnucleoside reverse transcriptase inhibitors (NNRTIs) have variable

154 Increased use of nonnucleoside reverse transcriptase inhibitors (NNRTIs) in pregnant an

155 lence levels of resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs) measured in th

156 iral therapy (ART) containing non-nucleoside reverse transcriptase inhibitors (NNRTIs) might compromi

157 Nonnucleoside reverse transcriptase inhibitors (NNRTIs) play a central

158 e prevalence of resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs) reached 45% (9

159 (ADAMs) are a unique class of non-nucleoside reverse transcriptase inhibitors (NNRTIs) that are capab

160 Nonnucleoside reverse transcriptase inhibitors (NNRTIs) that target th

161 Only the non-nucleoside reverse transcriptase inhibitors (NNRTIs) were associate

162 ation of a clinical candidate non-nucleoside reverse transcriptase inhibitors (NNRTIs) with a novel a

163 nt virus, next generation non-nucleoside HIV reverse transcriptase inhibitors (NNRTIs) with improved

164 nscriptase inhibitors (NRTIs), nonnucleoside reverse transcriptase inhibitors (NNRTIs), and protease

165 (1H)-ones were synthesized as non-nucleoside reverse transcriptase inhibitors (NNRTIs), and their bio

166 , is influenced by mutations, non-nucleoside reverse transcriptase inhibitors (NNRTIs), nucleotide su

167 ithin the class of allosteric non-nucleoside reverse transcriptase inhibitors (NNRTIs).

168 mainly driven by resistance to nonnucleoside reverse transcriptase inhibitors (NNRTIs).

169 articles and susceptibility to nonnucleoside reverse transcriptase inhibitors (NNRTIs).

170 Moderate (5%-15%) TDR to nonnucleoside reverse-transcriptase inhibitors (NNRTIs) was observed a

171 aining resistance mutations to nonnucleoside reverse-transcriptase inhibitors (NNRTIs).

172 riptase inhibitors [NRTIs] and nonnucleoside reverse transcriptase inhibitors [NNRTIs]), integrase st

173 in patients receiving PIs and nonnucleoside reverse transcriptase inhibitors [NNRTIs], and 60.3% [P

174 Here, we assessed the ability of nucleoside reverse-transcriptase inhibitor/nonnucleoside reverse-tr

175 ritonavir-boosted lopinavir and a nucleoside reverse transcriptase inhibitor (NRTI) backbone among th

176 fumarate (FTC/TDF) is a preferred nucleoside reverse transcriptase inhibitor (NRTI) backbone with lam

177 il fumarate is a standard-of-care nucleoside reverse transcriptase inhibitor (NRTI) backbone.

178 iated ART consisting of different nucleoside reverse transcriptase inhibitor (NRTI) backbones (zidovu

179 ns (47% vs 18%), all P = .01; and nucleoside reverse transcriptase inhibitor (NRTI) cross-resistance

180 MS-986001 is a thymidine analogue nucleoside reverse transcriptase inhibitor (NRTI) designed to maint

181 ine or emtricitabine plus another nucleoside reverse transcriptase inhibitor (NRTI) in fixed-dose com

182 of greater emergence of the K65R nucleoside reverse transcriptase inhibitor (NRTI) mutation in human

183 t frequent indicators of TDR were nucleoside reverse transcriptase inhibitor (NRTI) mutations (4.5%),

184 individuals; 15.8% had nucleoside/nucleotide reverse transcriptase inhibitor (NRTI) resistance, 9.8%

185 dation plays an important role in nucleoside reverse transcriptase inhibitor (NRTI) resistance.

186 Sixteen nucleoside reverse transcriptase inhibitor (NRTI) SDRMs accounted f

187 00 or >100,000 copies per mL) and nucleoside reverse transcriptase inhibitor (NRTI) selection.

188 n ART, and 20 (6.8%) started dual nucleoside reverse transcriptase inhibitor (NRTI) therapy.

189 S-p53 cells were treated with the nucleoside reverse transcriptase inhibitor (NRTI), 2',3'-dideoxycyt

190 , HIV-positive patients receiving nucleoside reverse transcriptase inhibitor (NRTI)-based ART, and HI

191 We hypothesized that nucleos(t)ide reverse transcriptase inhibitors (NRTI) may contribute t

192 Nucleoside reverse transcriptase inhibitors (NRTI) require intracel

193 inhibitor mutations; 41 (91%) had nucleoside reverse-transcriptase inhibitor (NRTI) mutations; 33 (73

194 ng the K103N mutation; 2 (4%) had nucleoside reverse-transcriptase inhibitor (NRTI) mutations; and 2

195 men and women initiating a triple nucleoside reverse-transcriptase inhibitor (NRTI) regimen versus re

196 namics of emerging nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI) resistance in hep

197 he presence of the Q151M multiple nucleoside reverse-transcriptase inhibitor (NRTI)--resistance compl

198 V) alone is attractive because of nucleoside reverse-transcriptase inhibitor (NRTI)-sparing benefits,

199 inhibitor (PI) strategy (PI plus nucleoside reverse transcriptase inhibitor [NRTI]; n=470), a non-nu

200 , zidovudine, and lamivudine (the nucleoside reverse-transcriptase inhibitor [NRTI] group) or lopinav

201 o two classes: nucleoside and non-nucleoside reverse transcriptase inhibitors (NRTIs and NNRTIs).

202 l resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors (NRTIs and NNRTIs).

203 ease inhibitor-sparing regimen of nucleoside reverse transcriptase inhibitors (NRTIs) + efavirenz, a

204 at entry and discontinued nucleoside analog reverse transcriptase inhibitors (NRTIs) after 6 weeks.

205 18 years who started ART with two nucleoside reverse transcriptase inhibitors (NRTIs) and a non-nucle

206 The potency of 2 nucleoside reverse transcriptase inhibitors (NRTIs) and efavirenz i

207 first-line regimen of PI/r plus 2 nucleoside reverse transcriptase inhibitors (NRTIs) and had at leas

208 development of drug resistance to nucleoside reverse transcriptase inhibitors (NRTIs) and nonnucleosi

209 Nucleoside reverse transcriptase inhibitors (NRTIs) are employed in

210 Nucleoside reverse transcriptase inhibitors (NRTIs) are mainstay th

211 Nucleoside reverse transcriptase inhibitors (NRTIs) are often inclu

212 ministered with two nucleoside or nucleotide reverse transcriptase inhibitors (NRTIs) are recommended

213 Nucleoside analog reverse transcriptase inhibitors (NRTIs) are the essenti

214 irenz 600 mg once a day with dual nucleoside reverse transcriptase inhibitors (NRTIs) for 24 weeks of

215 Mitochondrial toxicity limits nucleoside reverse transcriptase inhibitors (NRTIs) for acquired im

216 (Ed4T), have been investigated as nucleoside reverse transcriptase inhibitors (NRTIs) for treatment o

217 r pathway for HIV-1 resistance to nucleoside reverse transcriptase inhibitors (NRTIs) involves revers

218 the potency of nucleoside/nucleotide analog reverse transcriptase inhibitors (NRTIs) is an important

219 opinavir, and atazanavir) but not nucleoside reverse transcriptase inhibitors (NRTIs) or nonnucleosid

220 regimens for most patients are 2 nucleoside reverse transcriptase inhibitors (NRTIs) plus an integra

221 taggered interruption, whereby nucleos(t)ide reverse transcriptase inhibitors (NRTIs) were continued

222 Nucleoside reverse transcriptase inhibitors (NRTIs) with L-stereoch

223 ization method to classify TDR to nucleoside reverse transcriptase inhibitors (NRTIs), nonnucleoside

224 Because nucleoside reverse transcriptase inhibitors (NRTIs), the most commo

225 f the same resistance pathways to nucleoside reverse transcriptase inhibitors (NRTIs).

226 ease inhibitor plus nucleoside or nucleotide reverse transcriptase inhibitors (NRTIs).

227 mended initial regimens include 2 nucleoside reverse transcriptase inhibitors (NRTIs; abacavir/lamivu

228 The efficacy and toxic effects of nucleoside reverse-transcriptase inhibitors (NRTIs) are uncertain w

229 o paediatric trials have compared nucleoside reverse-transcriptase inhibitors (NRTIs) in first-line a

230 is expected to impair activity of nucleoside reverse-transcriptase inhibitors (NRTIs) in second-line

231 se-finding study of VCV plus dual nucleoside reverse-transcriptase inhibitors (NRTIs) in the treatmen

232 z or lopinavir-ritonavir plus two nucleoside reverse-transcriptase inhibitors (NRTIs) is recommended

233 The effect of nonthymidine nucleoside reverse-transcriptase inhibitors (NRTIs) on fat mitochon

234 ndard protease inhibitor plus two nucleoside reverse-transcriptase inhibitors (NRTIs) second-line com

235 The use of fixed-dose combination nucleoside reverse-transcriptase inhibitors (NRTIs) with a nonnucle

236 Subjects received nucleoside or nucleotide reverse-transcriptase inhibitors (NRTIs) with or without

237 o 12 HIV-1 inhibitors including 6 nucleoside reverse-transcriptase inhibitors (NRTIs), 4 non-nucleosi

238 sets of mutations in response to nucleoside reverse-transcriptase inhibitors (NRTIs).

239 V) therapy includes a backbone of nucleoside reverse-transcriptase inhibitors (NRTIs).

240 r, with adjustment of one or more nucleoside reverse-transcriptase inhibitors (NRTIs).

241 reverse transcriptase inhibitors (nucleoside reverse transcriptase inhibitors [NRTIs] and nonnucleosi

242 y associated with a nucleoside or nucleotide reverse transcriptase inhibitor (NtRTI)-sparing regimen.

243 ease inhibitor plus nucleoside or nucleotide reverse transcriptase inhibitors (NtRTIs) might be compr

244 ection includes two nucleoside or nucleotide reverse transcriptase inhibitors (NtRTIs), but these dru

245 ated with resistance to protease inhibitors, reverse transcriptase inhibitors (nucleoside reverse tra

246 o against wild-type HIV-1 and non-nucleoside reverse transcriptase inhibitor-, nucleoside reverse tra

247 Here we analyzed whether abacavir, an HIV-1 reverse transcriptase inhibitor often inducing severe de

248 We evaluated the effects of nucleoside reverse-transcriptase inhibitors on leukocyte-endotheliu

249 A nonnucleoside reverse transcriptase inhibitor or a protease inhibitor

250 her effective regimens include nonnucleoside reverse transcriptase inhibitors or boosted protease inh

251 d first-line regimens based on nonnucleoside reverse transcriptase inhibitors or integrase inhibitors

252 tase inhibitors (NRTIs) with a nonnucleoside reverse-transcriptase inhibitor or a ritonavir-boosted p

253 therapy (ART) with at least 1 nonnucleoside reverse-transcriptase inhibitor or protease inhibitor.

254 but not among mothers who used nonnucleoside reverse-transcriptase inhibitor or triple-nucleoside reg

255 of a first-line regimen of a non-nucleoside reverse transcriptase inhibitor plus two NtRTIs.

256 ooperative reactions, whereas non-nucleoside reverse transcriptase inhibitors, protease inhibitors an

257 criptase inhibitors (NRTIs) or nonnucleoside reverse transcriptase inhibitors reduced trophoblast pro

258 In this model, reverse-transcriptase inhibitors rescued the neurotoxici

259 icipants with HIV-1 infection, nonnucleoside reverse-transcriptase inhibitor resistance mutations wer

260 Nucleoside reverse-transcriptase inhibitor resistance pathways in H

261 everse transcriptase (RT) and the nucleoside reverse transcriptase inhibitor-resistant mutation M184V

262 ere (1) the presence of low level nucleoside reverse-transcriptase inhibitor-resistant human immunode

263 resistance to 1 or more NNRTI or nucleoside reverse transcriptase inhibitors, respectively.

264 two decades since the approval of the first reverse transcriptase inhibitor (retrovir, GlaxoSmithKli

265 , and in combination with the non-nucleoside reverse transcriptase inhibitor rilpivirine.

266 IV dynamics under the influence of a 3TC D4T Reverse Transcriptase Inhibitors (RTI) drug regimen.

267 eened the efficacy of commercially available reverse transcriptase inhibitors (RTIs) at inhibiting th

268 ested to be a major substrate for TREX1, and reverse transcriptase inhibitors (RTIs) were proposed as

269 the host cells, such as entry inhibitors or reverse transcriptase inhibitors (RTIs), are ideal candi

270 ld-type HIV-1 strains and those resistant to reverse transcriptase inhibitors (RTIs).

271 -1 transmission and/or for use in nucleoside reverse transcriptase inhibitor-sparing antiretroviral r

272 bitors (NRTIs) + efavirenz, a non-nucleoside reverse transcriptase inhibitor-sparing regimen of NRTIs

273 ase inhibitors, nonnucleoside and nucleotide reverse transcriptase inhibitors TDR mutations, namely,

274 fidence interval, 0.07%-13.8%) nonnucleoside reverse-transcriptase inhibitor TDR was determined.

275 l phenyl ester prodrug of the nucleotide HIV reverse transcriptase inhibitor tenofovir (TFV; 9-[(2-ph

276 ntly dosed vaginal gels containing the HIV-1 reverse transcriptase inhibitor tenofovir protected pigt

277 enofovir alafenamide delivers the nucleotide reverse transcriptase inhibitor tenofovir to target cell

278 erapy (ART) containing the modern nucleoside reverse transcriptase inhibitor tenofovir.

279 mended initial regimens include 2 nucleoside reverse transcriptase inhibitors (tenofovir/emtricitabin

280 boosted protease inhibitor plus 2 nucleoside reverse transcriptase inhibitors (tenofovir/emtricitabin

281 We evaluated two long-acting reverse transcriptase inhibitors, tenofovir (TFV) and em

282 (ADAMs) are a unique class of non-nucleoside reverse transcriptase inhibitors that have potential val

283 etroviral medications, such as nonnucleoside reverse transcriptase inhibitors, the detection of these

284 the mechanisms by which nucleoside-analogue reverse transcriptase inhibitors, the most common class

285 ularly among those with mono/dual nucleoside reverse transcriptase inhibitor therapy prior to combina

286 hort of patients by selectively interrupting reverse transcriptase inhibitor therapy, and we found th

287 ide containing Spm8CHAS with an HIV-specific reverse transcriptase inhibitor to prevent both HIV and

288 elucidate potential mechanisms of nucleoside reverse-transcriptase inhibitor toxicities.

289 verse-transcriptase inhibitor and nucleoside reverse-transcriptase inhibitor transmitted drug resista

290 everse-transcriptase inhibitor/nonnucleoside reverse-transcriptase inhibitor treatment to restore the

291 Non-nucleotide reverse transcriptase inhibitor use was associated with

292 ociations between single and dual nucleoside reverse-transcriptase inhibitor use and possible mitocho

293 rdiovascular (CV) toxicity of the nucleoside reverse-transcriptase inhibitors used to treat human imm

294 Baseline drug resistance to nucleoside reverse transcriptase inhibitors was observed in 54.5% o

295 uring antiretroviral therapy with nucleoside reverse-transcriptase inhibitors was previously associat

296 Relevant mutations affecting nonnucleoside reverse transcriptase inhibitors were found in 32 of 133

297 d efavirenz, were open-label; the nucleoside reverse transcriptase inhibitors were prematurely unblin

298 Nucleotide-competing reverse transcriptase inhibitors were shown to bind reve

299 e or peptide scaffolds containing nucleoside reverse transcriptase inhibitors were synthesized.

300 Non-nucleoside reverse-transcriptase inhibitors, zidovudine, and didano